Ernexa Therapeutics Inc. Cost of Revenue
Ernexa Therapeutics Inc. (ERNA) reported Cost of Revenue of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2026-08-06
- Ernexa Therapeutics Inc. cost of revenue for the quarter ending 2026-06-30 was $0.00.
- Ernexa Therapeutics Inc. cost of revenue for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. cost of revenue for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. cost of revenue for the quarter ending 2024-09-30 was -$60.00K, a 150.00% decline year-over-year.
- Ernexa Therapeutics Inc. cost of revenue for fiscal 2024 was $96.00K, a 59.32% decline from fiscal 2023.
- Ernexa Therapeutics Inc. cost of revenue for fiscal 2023 was $236.00K.
- Ernexa Therapeutics Inc. cost of revenue for fiscal 2022 was $0.00.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$60.00K derived: sum of 2 quarters · filed 2026-03-13 | $35.00K derived: sum of 3 quarters · filed 2026-03-13 | $96.00K 10-K · filed 2026-03-13 |
| 2024-09-30 | -$60.00K 10-Q · filed 2024-11-12 | $35.00K derived: sum of 2 quarters · filed 2025-08-13 | $96.00K 10-Q · filed 2024-11-12 | $162.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-06-30 | $95.00K 10-Q · filed 2025-08-13 | $156.00K 10-Q · filed 2025-08-13 | $222.00K derived: sum of 3 quarters · filed 2025-08-13 | $342.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $61.00K 10-Q · filed 2025-05-07 | $127.00K derived: sum of 2 quarters · filed 2025-05-07 | $247.00K derived: sum of 3 quarters · filed 2025-05-07 | $247.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $186.00K derived: sum of 2 quarters · filed 2025-03-12 | $186.00K derived: sum of 3 quarters · filed 2025-03-12 | $236.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | $120.00K 10-Q · filed 2024-11-12 | $120.00K derived: sum of 2 quarters · filed 2024-11-12 | $170.00K 10-Q · filed 2024-11-12 | $170.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $50.00K 10-Q · filed 2024-08-13 | $50.00K derived: sum of 3 quarters · filed 2024-08-13 | $50.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $50.00K 10-Q · filed 2024-05-14 | $50.00K derived: sum of 2 quarters · filed 2024-05-14 | $50.00K derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |